Ferhat Şirinyıldız, Gökhan Cesur

Apelin 13’ün Deneysel Ülseratif Kolit Üzerindeki Etkilerinin Araştırılması

Amaç: Bu çalışmanın amacı, trinitrobenzen sülfonik asit (TNBS) ile indüklenen deneysel kolit modelinde apelin (APL) 13’ün etkilerini araştırmaktır. APL-13’ün kolon enflamasyonunda proliferatif ve antiinflamatuvar etkilerinin yanında antioksidan etkilerini biyokimyasal ve histopatolojik analizler ile test etmektir. Gereç ve Yöntemler: Kırk beş adet Wistar albino sıçan, kontrol, sham kontrol, APL kontrol, kolit (TNBS), kolit + Etanol ve kolit + APL olmak üzere altı gruba ayrıldı. Kontrol grubuna tedavi uygulanmadan standart yem verildi. Sham grubu ve kolit grubuna intrarektal salin ve TNBS verildi. APL kontrol grubuna APL uygulandı, ancak kolit yapılmadı. Kolit + Etanol ve Kolit + APL gruplarına kolit sonrası 3 gün boyunca 100 μg/kg APL intraperitoneal olarak (i.p.) verildi. Dokuların biyokimyasal analizi için miyeloperoksidaz (MPO), malonildialdehit (MDA), süperoksit dismutaz, katalaz ve glutatyon seviyeleri ölçüldü. Histopatolojik değerlendirmeler gerçekleştirildi. Bulgular: TNBS grubu hayvanların MDA ve MPO düzeylerinde anlamlı düzeyde artış olduğu ve antioksidan parametrelerinin önemli ölçüde azaldığı görüldü. APL-13 uygulamasının TNBS grubuna göre kolon MDA ve MPO seviyelerinde önemli bir düşüş sağladığı ve antioksidan parametrelerin ise TNBS grubuna göre önemli ölçüde arttığı gösterildi. TNBS + APL grubunun histopatolojik değerlendirmesinde TNBS grubuna göre daha az mukozal hasar, nekroz ve ödem olduğu gözlendi. Sonuç: Sonuç olarak, çalışmamız APL-13’ün TNBS’ye bağlı ülseratif kolit üzerinde terapötik etkileri olduğunu göstermiştir. APL-13, ülseratif kolitin olumsuz etkilerini ortadan kaldırmak için kullanılabilecek etkili bir madde olabilir.

Investigation of the Effects of Apelin 13 on Experimental Ulcerative Colitis

Objective: The aim of this study was to investigate the effects of apelin (APL)-13 in a trinitrobenzenesulphonic acid (TNBS) induced experimental colitis model. It is also to test whether APL-13 has an antioxidant effect in addition to its proliferative and anti-inflammatory effect in colon inflammation by looking at antioxidant parameters. Materials and Methods: Forty-five Wistar albino rats were divided into six groups as control, sham control, APL control, colitis (TNBS), colitis + ethanol, and colitis + APL. The control group was fed a standard diet without any treatment. The sham group was treated in the same colitis group, but saline was given instead of TNBS. The APL control group was given APL, but no colitis was induced. Colitis + ethanol and colitis + APL group was given ethanol and 100 μg/kg APL intraperitoneally (i.p.) for 3 days after colitis. For the biochemical analysis of the tissues, levels of myeloperoxidase (MPO), malonyldialdehyde (MDA), superoxide dismutase, catalase and glutathione were measured. Histopathological observations occurred. Results: There were significantly increased MDA and MPO levels the animals that were grouped as TNBS and the antioxidant parameters were shown significantly decreased. Administration of APL-13 did make a significant decrease in colon MDA and MPO levels and antioxidant parameters were shown significantly increased compared to TNBS groups. The histological image of the TNBS + APL group was observed to have reduced mucosal damage, necrosis and edema compared with the TNBS group. Conclusion: In conclusion, our study showed that APL-13 has therapeutic effects on TNBS induced ulcerative colitis. APL-13 may be an effective substance that can be used to eliminate the negative effects of ulcerative colitis

PDF

___

1. Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 2004; 50: 81-92.
2. Fukuda Y, Tao Y, Tomita T, Hori K, Fukunaga KI, Noguchi T, et al. A traditional Japanese medicine mitigates TNBS-induced colitis in rats. Scand J Gastroenterol 2006; 41: 1183-9.
3. Sartor RB. Pathogenic and clinical relevance of cytokines in inflammatory bowel disease. Immunol Res 1991; 10: 465-71.
4. Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, Van Hogezand RA, Lamers CB, et al. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol 2003; 201: 17-27.
5. Hermanowicz A, Gibson PR, Jewell DP. The role of phagocytes in inflammatory bowel disease. Clin Sci (Lond)1985; 69: 241-9.
6. Han S, Wang G, Qiu S, de la Motte C, Wang HQ, Gomez G, et al. Increased colonic apelin production in rodents with experimental colitis and in humans with IBD. Regul Pept 2007; 142: 131-7.
7. Han S, Wang G, Qi X, Englander EW, Greeley GH. Involvement of a Stat3 binding site in inflammation-induced enteric apelin expression. Am J Physiol Gastrointest Liver Physiol 2008; 295: 1068-78.
8. Sabry MM, Ramadan NM, Al Dreny BA, Rashed LA, Abo El Enein A. Protective effect of apelin preconditioning in a rat model of hepatic ischemia reperfusion injury; possible interaction between the apelin/APJ system, Ang II/AT1R system and eNOS. United European Gastroenterol 2019; 7: 689-98.
9. Emam MN, Abo El geit RE. Promoting effect of adipocytokine, apelin, on hepatic injury in caerulein-induced acute pancreatitis in rats: Apelin on AP-induced hepatic injury. Alexandria Journal of Medicine 2016; 52: 309-15.
10. Castan-Laurell I, Dray C, Attané C, Duparc T, Knauf, C, Valet P. Apelin, diabetes, and obesity. Endocrine 2011; 40: 1-9.
11. Necefli A, Tulumoğlu B, Giriş M, Barbaros U, Gündüz M, Olgaç V, et al. The effect of melatonin on TNBS-induced colitis. Dig Dis Sci 2006; 51: 1538-45.
12. Ek RO, Serter M, Ergin K, Cecen S, Unsal C, Yildiz Y, et al. Protective effects of citicoline on TNBS-induced experimental colitis in rats. Int J Clin Exp Med 2014; 7: 989-97.
13. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, Navarro E, Martınez-Salmerón JF, Garcıa-Pugés A, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol 1999; 94: 427-33.
14. Brenna Ø, Furnes MW, Drozdov I, van Beelen Granlund A, Flatberg A, Sandvik AK, et al. Relevance of TNBS-colitis in rats: A methodological study with endoscopic, historical and transcriptomic characterization and correlation to IBD. PLoS One 2013; 8: e54543.
15. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol 2000; 19: 51-62.
16. da Silva MS, Sánchez-Fidalgo S, Talero E, Cárdeno A, da Silva MA, Villegas W, et al. Anti-inflammatory intestinal activity of Abarema cochliacarpos (Gomes) Barneby & Grimes in TNBS colitis model. J Ethnopharmacol 2010; 128: 467-75.
17. Fujino K, Takami Y, Sebastian G, Ludwig KA, Mantyh CR. Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis. J Gastrointest Surg 2004; 8: 842-7.
18. Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P, et al. Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-α, NF-κBp65, IL-6) in TNBSinduced colitis in rats. Mediators Inflamm 2006; 2006: 92642.
19. Antushevich H, Wójcik M. Review: Apelin in disease. Clin Chim Acta 2018; 483: 241-8.
20. Bircan B, Çakır M, Kırbağ S, Gül HF. Effect of apelin hormone on renal ischemia/reperfusion induced oxidative damage in rats. Ren Fail 2016; 38: 1122-8.
21. Sagiroglu T, Aksoy MB, Sagiroglu G, Tozkir H, Oguz S, Yalta T, et al. Effect of leptin and apelin preconditioning on hepatic ischemia reperfusion injury in rats. Indian J Surg 2014; 76: 111-6.
22. Foussal C, Lairez O, Calise D, Pathak A, Guilbeau-Frugier C, Valet P, et al. Activation of catalase by apelin prevents oxidative stress- linked cardiac hypertrophy. FEBS Lett 2010; 584: 2363-70.
23. Xu Z, Li Z. Experimental study on the role of Apelin-13 in alleviating spinal cord ischemia reperfusion injury through suppressing autophagy. Drug Des Devel Ther 2020; 14: 1571-81.
24. Zhang J, Lin X, Xu J, Tang F. Apelin-13 reduces oxidative stress induced by uric acid via downregulation of renin-angiotensin system in adipose tissue. Toxicol Lett 2019; 305: 51-7.
25. Pisarenko OI, Lankin VZ, Konovalova GG, Serebryakova LI, Shulzhenko VS, Timoshin AA, et al. Apelin-12 and its structural analog enhance antioxidant defense in experimental myocardial ischemia and reperfusion. Mol Cell Biochem 2014; 391: 241-50